リサンキズマブ、中等症以上の活動期潰瘍性大腸炎の成人患者への治療薬として欧州医薬品委員会が肯定的見解

６．Mehta, F. (2016) "Report: economic implications of inflammatory bowel disease and its management." Am J Manag Care. 22(3 Suppl):51-60.

７．Van Assche, G. et al. (2016) "Burden of Disease and Patient-Reported Outcomes in Patients With Moderate to Severe Ulcerative Colitis in the Last 12 Months - Multicenter European Cohort Study." Dig Liver Dis. 48(6):592-600. doi:10.1016/j.dld.2016.01.011.

８．Dave, M. Loftus, EV Jr. (2012) "Mucosal Healing in Inflammatory Bowel Disease-A True Paradigm of Success?" Gastroenterol Hepatol (N Y). 8(1):29-38.

９．Turner, D. et al. (2021) "STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target Strategies in IBD." Gastroenterology. 160(5):1570-1583. doi:10.1053/j.gastro.2020.12.031.

10．Colombel, J.F. et al. (2020) "Outcomes and Strategies to Support a Treat-to-Target Approach in Inflammatory Bowel Disease: A Systematic Review." J Crohns Colitis. 14(2):254-266. doi:10.1093/ecco-jcc/jjz131.